Moleculin Biotech, Inc.

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout